A Three-Part Study Of GSK580416 In Healthy Subjects

GlaxoSmithKline48 enrolled

Overview

Studies for GSK580416 have been completed in rats and dogs. The main toxic effects seen in animals affected the digestive system and blood cells. Study OPS106400 will be the first administration of GSK580416 in humans. Parts A and B of this study will examine the safety, tolerability, and pharmacokinetics of increasing single doses of GSK580416 with reference to placebo. Part C of the study will assess the effect of food on the safety, tolerability, and pharmacokinetics of a single dose of GSK580416 in healthy subjects.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

SINGLE

Enrollment

Conditions

Respiratory Tract Infection Infections, Bacterial

Interventions

GSK580416DRUG

Eligibility

Sex: ALLMin age: 18 YearsMax age: 55 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion criteria: * Healthy as determined by a physician * Healthy male or female of non-child bearing potential between 18 and 55 years of age (inclusive) * Body weight \> = 50 kg and BMI between 19 and 30 kg/m2 (inclusive) Exclusion criteria: * Positive HIV antibody, Hepatitis B surface antigen or Hepatitis C antibody with 3 months of screening * Male and female subjects not willing to follow study specified contraceptive methods * Subjects taking any recreational drugs * Regular use of tobacco- or nicotine-containing products within 6 months prior to screening * Has participated in a clinical trial and have not received a drug within 30 days before the dose of study drug * Has exposed to more than 4 new chemical entities within 12 months before the first dosing day * Use of prescription or over-the-counter medications within 7 days or 5 half-lives (whichever is longer) prior to the first dose of study drug * Use of St. John's Wort within 28 days before the first dose of study drug * Subjects not willing to follow study specified life style restrictions * Blood donation in excess of 500 mL within a 56 days period

Locations (1)

GSK Investigational Site

Randwick, Sydney, New South Wales, Australia

Outcomes

Primary Outcomes

Safety assessments (adverse event, ECG and vital sign) will be performed during the study. Blood samples to determine drug levels in the body will be collected during the study.

Time frame: during the study

Secondary Outcomes

Blood samples to determine drug levels in the body will be collected during the study.

Time frame: during the study

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.